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Abstract. High levels of antibodies to multiple antigens may be more strongly associated with protection from
infection than antibodies to a single antigen. Antibody-associated protection against Plasmodium falciparum infection
was assessed in a cohort of 68 adults living in an area of holoendemic malaria in Kenya. Antibodies to the pre-
erythrocytic antigens circumsporozoite protein (CSP), liver-stage antigen-1 (LSA-1), thrombospondin-related adhesive
protein (TRAP), and blood-stage antigens apical membrane antigen-1 (AMA-1), erythrocyte binding antigen-175
(EBA-175), and merozoite surface protein 1 (MSP-1) were tested. Peptides were used for CSP (NANP repeat) and
LSA-1 (central repeat), and recombinant antigens were used for TRAP (aa D48–K394), AMA-1 (ectodomain, non-
glycosylated), EBA-175 (non-glycosylated), and MSP-1 (MSP-119). Weekly microscopy testing for P. falciparum infec-
tion was performed over a 12-week period after drug-mediated clearance of P. falciparum parasitemia. Individuals with
high levels of IgG antibodies (> 2 arbitrary units) to CSP, LSA-1, and TRAP had a 57% decrease in the risk of infection
(95% confidence interval  20–77%, P  0.016). This decreased risk remained significant after adjustment for age, prior
parasitemia, bed net use, sickle cell trait, and village of residence. In contrast, protection against infection did not
correlate with high levels of IgG antibodies to blood-stage antigens or IgM antibodies to pre-erythrocytic or blood-stage
antigens. High levels of IgG antibodies to CSP, LSA-1, and TRAP may be useful immune correlates of protection against
P. falciparum infection in malaria-endemic populations.
INTRODUCTION
Identification of reliable and reproducible immune corre-
lates of protection against Plasmodium falciparum infection
will be important in the development and testing of malaria
vaccines. Results from studies of rodent malaria models and
humans with partial immunity induced by irradiated sporo-
zoites or repeated natural infections suggest that both anti-
body and cytokine responses to pre-erythrocytic antigens con-
tribute to or correlate with protection against P. falciparum
infection.1–7 However, neither antibody nor cytokine re-
sponses to circumsporozoite protein (CSP) correlated with
protection against P. falciparum infection in malaria-naive
volunteers immunized with the RTS,S CSP vaccine.8,9 The
identification of immune correlates of protection that can be
used to evaluate vaccine immunogenicity and efficacy in
populations where malaria is endemic presents additional
challenges. First, most individuals will have pre-existing im-
mune responses to multiple pre-erythrocytic antigens. Sec-
ond, the time at which and number of sporozoites to which an
individual has been exposed cannot be controlled. Third, im-
mune responses and partial resistance to blood-stage para-
sites co-exists in persons who have been repeatedly infected,
thus complicating interpretation of endpoints such as the
appearance of asexual parasitemia. Despite these con-
straints, some studies have shown that cytokine responses to
pre-erythrocytic antigens such as liver-stage antigen-1 (LSA-
1)10–14 are associated with protection from P. falciparum in-
fection in malaria-endemic areas. In addition, a recent study
of the RTS,S CSP vaccine in individuals living in a malaria-
endemic area demonstrated that CD4-mediated interferon-
(IFN-) responses to CSP were associated with protection
from infection.15 In contrast, observations made in some of
the same populations have failed to document a correlation of
protection with antibodies to LSA-110,16 and circumsporozo-
ite protein (CSP),16 although a trend toward protection was
seen with antibodies to CSP in the RTS,S vaccine study.15
Given that persons living in malaria-holoendemic areas have
experienced repeated natural infections since childhood and
develop antibody responses to multiple pre-erythrocytic an-
tigens, we hypothesized that the presence of high levels of
antibodies to multiple as opposed to single antigens may be a
more robust correlate of protection from infection.
In contrast, antibodies to blood-stage antigens, which act
primarily on the growth of parasites undergoing growth in red
blood cells, would more likely be associated with protection
from high-density parasitemia and morbidity. To test this hy-
pothesis, we measured IgG and IgM antibodies to six P. fal-
ciparum vaccine candidate antigens in adults residing in a
malaria-holoendemic area of Kenya. High levels of antibodies
to these antigens individually and in combination were com-
pared with time and risk of re-infection after clearance of
pre-existing blood-stage parasitemia. This study was per-
formed in adults because the high levels of immunity in this
population would allow us the best chance to identify robust
immune correlates of protection from infection. Knowledge
of likely correlates would be very useful in planning such a
study in children, who are at the highest risk of complications
from malaria. Antigens to which antibodies were tested in-
cluded the pre-erythrocytic antigens CSP, LSA-1 and thro-
mobospondin related adhesive protein (TRAP) and the
blood-stage antigens apical-membrane antigen-1 (AMA-1),
erythrocyte-binding antigen-175 (EBA-175), and merozoite
surface protein-1 (MSP-1).
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MATERIALS AND METHODS
Study site and participants. The study was conducted in
Kanyawegi, Nyanza Province, Kenya from August to Decem-
ber 2001. The population of Kanyawegi is approximately
3,500, and it is located in a malaria- endemic region that is
considered holoendemic.17 All study participants were  15
years old (median age  37.5 years). Seventy-seven persons
(44 women and 33 men) were successfully recruited for the
study. Exclusion criteria were pregnancy and use of anti-
malarial drugs within the previous two weeks. Use of mos-
quito nets was ascertained for all study participants.
Treatment reinfection study. Recruitment was done after
community and individual meetings were held to explain the
nature and purpose of the study. Persons agreeing to partici-
pate were given quinine (600 mg orally every 8 hours) for five
days and doxycyline (100 mg orally every day) for seven days
to clear parasitemia. Blood for laboratory studies was ob-
tained by venipuncture prior to anti-malarial treatment. The
participants were followed for malaria infection by micro-
scopic inspection of blood smears obtained weekly for 14
weeks by pricking the finger with a lancet. Clearance of par-
asitemia was documented by microscopy and polymerase
chain reaction (PCR) testing two weeks after initial anti-
malarial administration. Persons who did not clear parasit-
emia by PCR testing were excluded from further analysis.
Time to re-infection was calculated as time to the appearance
of blood-stage parasites beginning two weeks after anti-
malarial drug administration (total follow-up time  12
weeks). Individuals who missed more than two weeks of
blood smear testing were included in analysis up to the time
of their last blood smear.
Blood was obtained immediately from persons who had
symptoms of malaria in the follow-up period, and a single
dose of sulfadoxine-pyrimethamine (600 mg of sulfadoxine
and 25 mg of pyrimethamine) was given to those with clinical
malaria, which was defined as 1) P. falciparum infection of
any density on blood smear and an axillary temperature 
37.5°C or a history of fever within the previous 24 hours; or 2)
P. falciparum parasitemia  5,000 parasites/L with any ma-
laria symptoms.
Informed consent and ethical approval. Written informed
consent was obtained from all participants. Ethical approval
for the study was granted by the Kenya Medical Research
Institute National Ethical Review Committee and the Insti-
tutional Review Board for Human Studies at University Hos-
pitals of Cleveland and Case Western Reserve University.
Microscopy and polymerase chain reaction testing for P.
falciparum infection and the hemoglobin S (HbS) mutation
(sickle cell trait). Malaria infection was diagnosed by micro-
scopic inspection of thick and thin blood smears as previously
described.18 Plasmodium falciparum infection was further
confirmed by nested PCR amplification of P. falciparum 18S
small subunit RNA as described by Snounou and others.19
The HbS mutation was detected by PCR amplification fol-
lowed by digestion with the restriction enzyme Bsu 361 as
described by Husain and others.20
Antibody testing by enzyme-linked immunosorbent assay
(ELISA). The presence of antibodies to CSP and LSA-1 was
tested using central repeat sequence peptides to which indi-
viduals from malaria-endemic areas have previously been ob-
served to have IgG antibodies. The (NANP)5 repeat pep-
tide21 was used for CSP, and the central amino acid repeat
sequence LAKEKLQGQQSDLEQERLAKEKLQ-EQQ-
SDLEQERLAKEKLQ (LSA-Rep)22 was used for LSA-1.
The presence of antibodies to TRAP, AMA-1, EBA-175 and
MSP-1 was tested using recombinant antigens. Recombinant
P. falciparum TRAP (3D7) was expressed in Escherichia coli
and provided by one of the authors (DEL). The gene frag-
ment encoding amino acids D48 to K394 was PCR-amplified
from the 3D7 strain of parasite genomic DNA using gene-
specific sense and antisense primers. Recombinant AMA-1
(ectodomain, non-glycosylated) and EBA-175 (glycosylated
and non-glycosylated) were expressed in Pichia pastoris and
provided by one of the authors (DLN). Since antibody levels
to glycosylated EBA-175 and non-glycosylated EBA-175
were similar, only the results of antibodies to the non-
glycosylated form are reported. Recombinant MSP-119 pro-
tein corresponding to the E-KNG variant was expressed in
Saccharomyces cerivisiae23 and provided by the Malaria Re-
search and Reference Reagent Resource Center (Manassas,
VA). In previous testing in this area, IgG antibodies from
adult sera most frequently recognized the E-KNG variant.
IgG antibodies were measured by an ELISA. The CSP and
LSA-1 peptides were dissolved in 0.01 M phosphate-buffered
saline (PBS) to a concentration of 10 g/mL, and recombi-
nant antigens were dissolved in 0.01 M PBS to concentrations
of 0.1 g/mL (AMA-1 and EBA-175), 0.2 g/mL (MSP-1),
and 0.5 g/mL (TRAP). Fifty microliters of antigen solution
was added to Immulon-4 plates (Dynex Technologies, Chan-
tilly, VA). Following overnight incubation at 4°C, washing
with PBS, 0.05% Tween 20, and blocking in 5% (w/v) non-fat
powdered milk in PBS, duplicate 50-L samples of serum
diluted 1:100 in 5% powdered milk were added to wells and
incubated for two hours at room temperature. After washing
with PBS, 0.05% Tween 20, 50 L of alkaline phosphatase–
conjugated goat anti-human IgG (Jackson ImmunoResearch,
West Grove, PA) diluted 1:1,000 in 5% powdered milk was
added and removed after one hour. After extensive washing
with PBS, 0.05% Tween 20, p-nitrophenylphosphate was
added in accordance with the manufacturer’s instructions
(Sigma Chemical Co., St. Louis, MO). Optical density (OD)
was measured at 405 nm.
IgG1, IgG2, IgG3, and IgG4 subclass antibodies were mea-
sured by ELISA with several adjustments. Phosphate-
buffered saline–3% bovine serum albumin (BSA) was used as
blocking solution and PBS-1% BSA was used as diluent.
Mouse anti-human IgG subclass biotinylated antibodies
(Zymed Laboratories, San Francisco, CA) diluted 1:1,000
were added after incubation of antigen-coated microtiter
wells with human sera and washing with PBS, 0.05% Tween
20. Plates were washed again with PBS, 0.05% Tween 20 after
a 45-minute incubation at room temperature and streptavi-
din-conjugated alkaline phosphatase (Jackson ImmunoRe-
search) diluted 1:2,000 in diluent was added. Plates were
washed with PBS, 0.05% Tween 20 after a 30-minute incuba-
tion period and p-nitrophenylphosphate was then added and
the OD at 405 nm was measured.
IgM antibodies were tested by ELISA with the following
adjustments. Seablock buffer (Pierce Biotechnology, Rock-
ford, IL) was used as blocking buffer and diluent, and goat
anti-human alkaline phosphatase–conjugated IgM (Southern
Biotech, Birmingham, AL) at a dilution of 1:4,000 was used to
detect IgM.
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Antibody levels were expressed in arbitrary units (AU),
which are calculated by dividing the OD generated by the test
sample by the mean OD plus 3 SD generated by samples from
40 North Americans never exposed to malaria. Sera from 9
North American control subjects with OD values representa-
tive of the 40 North American samples initially tested were
used on individual plates. Values  1.0 AU were considered
positive. The OD values for the AU cut-off for IgG antibodies
to CSP, LSA-1, TRAP, AMA-1, EBA-175, and MSP-1 were
0.066, 0.049, 0.130, 0.240, 0.102, and 0.029, respectively.
Samples were tested on two days, with positive controls of
individuals with known antibodies to these antigens on each
plate, and the values of positive controls were similar between
days. Mean OD values for positive controls for IgG antibod-
ies to CSP, LSA-1, TRAP, AMA-1, EBA-175, and MSP-1
were 1.49, 1.02, 0.65, 0.86, 0.58, and 1.40, respectively. To
assess if antibody AU correlated with antibody titers, anti-
body titers (1:100–1:51,200) were assessed in all 68 individuals
for LSA-1. Correlation between AU and titer for LSA-1 was
very strong (Spearman’s   0.76, P < 0.0001).
Statistical analysis. Since antibodies to individual antigens
were present in up to 87% of the study participants, time to
re-infection was assessed in individuals with high levels of
antibodies. The threshold for high levels of antibodies was
arbitrarily set at 2 AU, or twice the threshold for a positive
response. This threshold allowed differentiation of a subset of
individuals for each antigen and provided enough numbers
with high level of antibodies to all three pre-erythrocytic or
blood-stage antigens to allow comparisons between those
with and without high levels of antibodies. Since exploration
of higher thresholds would have involved multiple compari-
sons, this was not conducted in the initial analysis.
Correlations between continuous variables, e.g., antibody
levels and age, were assessed by Spearman’s rank correlation.
Associations between categorical variables, e.g., presence of
HbS and antibodies to specific antigens, were assessed by
chi-square analysis. Kaplan-Meier survival analysis and the
log-rank test were used to compare the time to development
of P. falciparum parasitemia in study participants with and
without high levels of IgG antibodies to individual antigens or
to all three pre-erythrocytic or all three blood-stage antigens.
Risk of infection was assessed by Cox proportional hazards
analysis. Multiple comparisons were adjusted for by the Bon-
ferroni correction. Age, HbS status, bed net use, malaria in-
fection status prior to anti-malarial treatment, and village of
residence were adjusted for in the final Cox model. Bed nets
were used by 7.4% of the individuals, and 27.9% had HbAS
(sickle cell trait). The trial sample size was designed to have
80% power to detect a 50% decrease in infection in individu-
als with high levels of antibodies, assuming the presence of
high level of antibodies in at least one-third of the samples
and a cumulative malaria infection incidence  75%. Statis-
tical analysis was done with Stata 8.0 (Stata Corporation, Col-
lege Station, TX).
RESULTS
Infection with P. falciparum. Seventy-seven individuals
were enrolled in the study. Two weeks after treatment, two
individuals had persistent P. falciparum blood-stage infection
by microscopy testing, and seven additional individuals had
persistent infection by PCR testing. Analysis of time to re-
infection and risk of infection was performed on the remain-
ing 68 individuals. Twelve individuals (17.6%) remained free
of blood-stage infection for the entire 12-week follow-up pe-
riod.
Frequencies and levels of antibodies to P. falciparum pre-
erythrocytic and blood-stage antigens. IgG antibodies to the
pre-erythrocytic or blood-stage antigens tested were present
in 72–88% of study participants. Levels of IgG antibodies to
the pre-erythrocytic antigens CSP, LSA-1, and TRAP were
generally high (Table 1). High levels of IgG antibodies (> 2
AU) were present in 60–76% of the individuals (Table 2).
IgG antibodies to all antigens were almost exclusively of the
IgG1 and IgG3 subclasses. Less than 4% of all individuals had
IgG2 antibodies to any antigen except LSA-1 (16%). Only
4% of the participants had IgG4 antibodies to any of the
antigens studied. The frequencies of IgG1, IgG3 and IgM
antibodies were more variable than those of IgG antibodies
(Table 1).
IgG antibodies to the various antigens correlated weakly
with each other, with the exception of LSA-1 and TRAP
(Spearman’s   0.50, P < 0.0001). In contrast, IgM antibod-
ies to all of the antigens correlated strongly with each other
(Spearman’s   0.58–0.89, all P values < 0.0001). IgM to
LSA-1 was more frequent in persons with parasitemia than in
those without parasitemia at the beginning of the study
(85.7% versus 53.8%, P  0.004, by chi-square test). There
was no correlation between blood-stage infection or parasite
density prior to the administration of anti-malarial drugs and
IgG, IgG subclass, or IgM antibodies to any of the antigens
tested. Age was also not associated with antibody level to any
antigen except CSP, for which IgG, IgG1, and IgG3 antibody
levels correlated significantly with age (Spearman’s   0.42,
0.32, and 0.33, P  0.003, 0.008, and 0.006, respectively).
TABLE 1
Antibody frequencies and levels (AU) to Plasmodium falciparum antigens in Kenyan adults*
Antigen










CSP 88% 6.38 (6.99) 54% 1.18 (1.73) 46% 0.87 (1.18) 50% 0.98 (3.31)
LSA-1 78% 4.25 (8.14) 74% 1.95 (3.18) 87% 2.61 (5.4) 57% 1.64 (7.2)
TRAP 87% 3.82 (4.15) 28% 0.58 (0.76) 85% 3.27 (3.39) 65% 1.91 (3.26)
AMA-1 88% 2.24 (3.16) 53% 1.15 (1.89) 90% 2.75 (2.15) 32% 0.51 (1.21)
EBA-175 72% 3.61 (7.52) 25% 0.48 (0.72) 53% 1.17 (2.06) 28% 0.38 (1.14)
MSP-1 76% 2.78 (10.2) 31% 0.57 (0.75) 62% 2.11 (5.72) 81% 6.23 (23.33)
* AU  Arbitrary unit (see Materials and Methods); IQR  interquartile range (third quartile value minus first quartile value); CSP  circumsporozoite protein; LSA-1  liver-stage antigen
1; TRAP  thrombospondin related adhesive protein; AMA-1  apical membrane antigen-1; EBA 175  erythrocyte-binding antigen 175; MSP-1  merozoite surface protein 1.
JOHN AND OTHERS224
IgG antibodies to pre-erythrocytic and blood-stage anti-
gens and risk of re-infection. Time to and risk of re-infection
did not differ significantly for study participants with or with-
out high levels of IgG antibodies to any antigen considered
individually (Table 2). When antibody levels were modeled as
continuous variables in the Cox model, there were trends
toward decreased risk of infection with increasing antibody
levels to CSP (P  0.09) and TRAP (P  0.17). Persons with
high levels of IgG antibodies (AU > 2) to all three of the
pre-erythrocytic antigens (CSP, LSA-1, and TRAP), compris-
ing 46% of the total study participants, had a significantly
delayed time to re-infection and decreased risk of infection
compared with those without high levels of IgG to these an-
tigens. Median times to re-infection for individuals with and
without high levels of antibodies to CSP, LSA-1, and TRAP
were 61 and 38 days, respectively (P  0.012, Figure 1), and
individuals with high levels of antibodies to CSP, LSA-1, and
TRAP had a 57% decrease in risk of infection (95% confi-
dence interval [CI]  20–77%, P  0.016). After adjustment
for age, initial P. falciparum infection, hemoglobin S status,
use of mosquito nets, and village of residence, risk of infection
in individuals with high levels of IgG to CSP, LSA-1, and
TRAP remained 55% lower than in individuals without these
antibodies (95% CI  9–78%, P  0.028). High levels of
antibodies to any two of the three pre-erythrocytic antigens
produced a more modest, non-significant protective effect.
High-density parasitemia (> 5,000 parasites/L) developed in
2 (6.4%) of 31 individuals with high levels of IgG antibodies
to CSP, LSA-1, and TRAP, compared with 5 (13.5%) of 37
individuals without high levels of antibodies to these antigens
(P  0.34, by chi-square test). Non-significant trends toward
protection from infection were seen for both high levels of
IgG1 and IgG3 to CSP, LSA-1, and TRAP after controlling
for potential confounding factors (hazard ratio [HR]  0.67,
95% CI  0.33–1.34, P  0.25 and HR  0.50, 95% CI 
0.22–1.15, P  0.10, respectively).
In contrast, time to re-infection and risk of infection did not
differ between groups of individuals with and without high
levels of antibodies to the three blood-stage antigens AMA-1,
EBA-175, and MSP-1 (Figure 2), although a trend toward a
decreased risk of infection was seen was increasing IgG anti-
body levels to AMA-1 (P  0.14). High-density parasitemia
was not different in those with and without high levels of
antibodies to blood-stage antigens. IgM antibodies to specific
or grouped pre-erythrocytic or blood-stage antigens did not
correlate with protection from infection.
DISCUSSION
The present study demonstrates that high levels of IgG
antibodies to multiple pre-erythrocytic antigens are associ-
ated with protection against P. falciparum infection in adults
living in a malaria-holoendemic area. The 57% reduction in
risk of re-infection (95% CI  20–77%) seen in Kenyan
adults with high levels of IgG antibodies to the pre-
erythrocytic antigens CSP, LSA-1, and TRAP remained after
adjustment for multiple other potentially protective factors.
These results provide new evidence that development of high
levels of immunity to multiple pre-erythrocytic antigens may
be important in protection against P. falciparum infection.
Several previous studies have suggested an association be-
tween antibodies to pre-erythrocytic antigens and protection
against P. falciparum infection. Two trials of the CSP-
containing vaccine RTS,S-AS02 conducted in the Gambia
TABLE 2
Risk of Plasmodium falciparum infection in adults with high-level
IgG antibodies to individual P. falciparum antigens*
Antigen Number with AU > 2 (%) Hazard ratio (95% CI)†
CSP 52 (76.4) 0.65 (0.34, 1.27)
LSA-1 46 (67.6) 0.70 (0.38, 1.28)
TRAP 49 (72.0) 0.72 (0.38, 1.33)
AMA-1 43 (63.2) 0.74 (0.41, 1.33)
EBA-175 45 (66.2) 1.25 (0.66, 2.36)
MSP-1 41 (60.3) 1.27 (0.69, 2.34)
* For definitions of abbreviations, see Table 1.
† Cox proportional hazards ratio. CI  confidence interval.
FIGURE 1. Time to Plasmodium falciparum reinfection in adults
with high levels of IgG antibodies to circumsporozoite protein (CSP),
liver-stage antigen-1 (LSA-1), and thrombospondin-related adhesive
protein (TRAP). Relative risk of infection  0.43, 95% confidence
interval  0.23–0.80.
FIGURE 2. Time to Plasmodium falciparum reinfection in adults
with high level of IgG antibodies to apical membrane antigen-1
(AMA-1), erythrocyte binding antigen-175 (EBA-175), and merozo-
ite surface protein 1 (MSP-1). Relative risk of infection  1.04, 95%
confidence interval  0.54–2.02. NS  not significant.
ANTIBODIES TO P. FALCIPARUM ANTIGENS 225
documented an association or trend between antibodies to
CSP and protection against infection. In the first study, a CSP
antibody level > 2.7 mg/L prior to vaccination correlated with
a 49% decrease in risk of infection (95% CI  24–66%) that
was independent of vaccination status.24 In the second study,
a trend toward delayed time to infection was seen in vacci-
nated individuals with higher antibody levels to CSP, al-
though this did not achieve statistical significance.15 In the
present study, a similar trend toward decreased infection was
seen in individuals with high levels of antibodies to CSP. We
chose a fixed AU cut-off level prior to determining associa-
tion with time to re-infection to avoid generation of spurious
associations by multiple comparisons. However, without a
reference antibody concentration, we were unable to measure
exact concentrations of antibodies to CSP, and the cut-off we
chose may have been significantly lower than 2.7 mg/L. Ex-
ploratory analysis showed that the choice of a cut-off AU of
3 for CSP was more strongly associated with protection (P 
0.07), but cut-offs above this level were not associated with
protection. Trends toward protection from infection were
seen in individuals with high levels of IgG1 and IgG3 subclass
antibodies to CSP, LSA-1, and TRAP. The lack of statistical
significance for these associations may reflect the smaller
numbers of individuals with high levels of subclass antibodies
to all three antigens (28 individuals for IgG1 and 16 individu-
als for IgG3).
Earlier studies in children also provide evidence that anti-
bodies to LSA-1 and TRAP may be associated with protec-
tion from malaria infection and disease. Antibodies to LSA-1
correlated with more rapid parasite clearance time12 and pro-
tection from clinical malaria25 in Gabon, and antibodies to
TRAP correlated with a decrease in high-density parasit-
emia26 and decreased infection16 in children in other malaria-
endemic areas of Africa. Observations of adults have not
demonstrated a correlation a protection with antibodies to
LSA-110,27 or TRAP,16 but these reports did not examine the
presence of high levels of antibodies to multiple pre-
erythrocytic antigens.
Antibodies to pre-erythrocytic antigens may be surrogate
markers for other immune processes or, in part, mediate pro-
tection against infection. In vitro and in vivo studies demon-
strating that antibodies to CSP and TRAP impair or com-
pletely prevent infection in murine malaria models2,28,29 pro-
vide biologic evidence to support the possible causal
association of these antibodies with protection. At the same
time, it is well established the T cell responses involving
IFN- and other cytokines mediate protection against liver-
stage malaria.1,6,30,31 It is not possible to evaluate or quantify
directly the level of protection directed against liver-stage
malaria in humans. IgG antibody levels in the study partici-
pants were unrelated to IFN- or interleukin-10 responses to
TRAP or LSA-1 peptides measured concurrently (John CC,
Moormann AM, unpublished data), suggesting that the two
processes may be independently regulated in persons with
natural infection. One potential mechanism for antibody-
related protection is the combined effects of antibodies that
target different steps during the pre-erythrocytic phase of in-
fection life cycle. Circumsporozoite protein is important in
adhesion of the sporozoite to the basolateral membrane of
the hepatocyte,32,33 and monoclonal antibodies to CSP inhibit
parasite invasion of hepatoma cells.28 Thrombospondin-
related adhesive protein is essential for sporozoite gliding mo-
tility7 and hepatocyte invasion,29 and antibodies to TRAP
have also been shown to prevent sporozoite invasion of hepa-
tocytes.2,4 Antibodies to LSA-1 may act to augment antibody-
dependent cellular inhibition of parasite growth or to increase
clearance of liver-stage merozoites just prior to their release
into the bloodstream.34 In the multi-step process of pre-
erythrocytic infection, antibodies to a single antigen, which
inhibit a single step in the infection cycle (e.g., sporozoite
attachment via CSP) may be significantly less effective in pre-
vention of infection than antibodies to multiple antigens,
which inhibit several sequential steps.
Recent proteomic studies have showed expression in the
sporozoite of antigens traditionally considered blood-stage
antigens, including var and rif gene variant proteins,35 AMA-
1,35,36 and EBA-175.37 One study demonstrated that antibod-
ies to AMA-1 blocked sporozoite invasion of hepatocytes,36
and, interestingly, in the present study, a trend toward pro-
tection from infection was seen with high levels of antibodies
to AMA-1, but not to EBA-175 or MSP-1. Several previous
studies have demonstrated an association with protection
from disease in children with antibodies to MSP-1.38–41 The
present study was conducted in adults and was a study of
protection from infection. We were not able to test protection
from disease because too few of the adults in our study de-
veloped clinical disease during the study period. The different
study population (adults) and clinical endpoint (infection) in
our study when compared with prior studies may explain in
part why we did not see protection associated with antibodies
to MSP-1. Ongoing studies are assessing the relationship of
these antibodies to protection from disease in children in this
area.
The reasons why certain individuals have high levels of
antibodies to all three antigens while others do not remain
poorly understood. Exposure levels may be different across
the study area, but the association of protection with high
levels of antibodies to CSP, TRAP, and LSA-1 remained even
after inclusion of village area in a multivariate model. Alter-
natively, genetic factors or the presence of other infectious
diseases or illnesses may alter the ability to develop and main-
tain such antibodies. Since malaria vaccine programs in ho-
loendemic areas will target children, it will be important to
document how such antibody responses develop with age, and
to determine whether high levels of antibodies are stable over
time in children and adults in this population.
A caveat of this and most studies of antibodies to P. falci-
parum antigens is the lack of standardization of antibody con-
centrations. Calculation and expression of antibody levels by
comparison with reactivity of sera from persons not exposed
to malaria, which are inherently subject to variation from one
center to the next, were used here. As noted previously, the
cut-off level of 2 AU for high levels of antibodies, while
clearly reflecting strong responses, was arbitrary. In explor-
atory analyses done after the initial analysis, we found that for
each antigen there was an ideal cut-off value that corre-
sponded best with protection (AU > 2 for LSA-1, AU > 4 for
TRAP, and AU > 3 for CSP). However, initial assessment
using multiple cut-off values would have necessitated multiple
comparisons and limited power to detect significant associa-
tions. Trends toward delayed risk of infection were seen with
higher antibody levels to CSP and TRAP, supporting a dose-
response relationship with protection from infection for these
antigens. Arbitrary units assume a continuous linear relation-
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ship between OD at a fixed concentration and antibody titer,
and may be an inaccurate for either very low or very high
titers. Our titer testing for a single antigen (LSA-1) demon-
strated that overall, titers correlated well with AU for this
antigen, and for the relatively low AU cut-off (> 2) used for
high levels in this study, it is unlikely that titer measurement
would have made a difference in our assessment. Rigorous
comparison of antibody levels and cut-offs in various malaria-
endemic populations will require use of the same recombi-
nant antigens and development of antibody concentration
standards. Widely accepted criteria of the strength of anti-
body responses to these antigens, the likelihood of their cor-
relation with protection against infection, and greater under-
standing of the antecedents and modifiers of IgG antibodies
to pre-erythrocytic P. falciparum will be valuable in the
search for surrogate biomarkers that can used to guide and
test malaria vaccines in the field. The present study has pro-
vided cut-off values and candidate antigens to assess the pro-
tective effect of IgG antibodies in children. Future studies will
address whether the high levels of protection from infection
associated with these antibodies in adults are seen in children
in this area.
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